{"url_path":"/sec/aytu/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 EXHIBITS**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1385818/0001437749-26-016721-index.html","accession_number":"0001437749-26-016721","cik":"0001385818","ticker":"AYTU","issuer_name":"AYTU BIOPHARMA, INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1385818/0001437749-26-016721-index.html","primary_entity_key":"0001385818","primary_entity_name":"AYTU BIOPHARMA, INC"},"word_count":335,"has_tables":true,"body_markdown":"**ITEM 6. EXHIBITS**\n\n \n\n**Exhibit No.**\n\n \n\n**Description**\n\n4.1\n \n[Form of Amended 2023 Prefunded Warrant, previously filed as Exhibit 4.1 to the Company’s current report on Form 8-K as filed with the SEC on April 2, 2026, and incorporated herein by reference.](http://www.sec.gov/Archives/edgar/data/1385818/000143774926011116/ex_940876.htm)\n\n4.2\n \n[Form of Amended 2023 Tranche A Warrant, previously filed as Exhibit 4.2 to the Company’s current report on Form 8-K as filed with the SEC on April 2, 2026, and incorporated herein by reference.](http://www.sec.gov/Archives/edgar/data/1385818/000143774926011116/ex_940877.htm)\n\n4.3\n \n[Form of Amended 2025 Prefunded Warrant, previously filed as Exhibit 4.3 to the Company’s current report on Form 8-K as filed with the SEC on April 2, 2026, and incorporated herein by reference.](http://www.sec.gov/Archives/edgar/data/1385818/000143774926011116/ex_940878.htm)\n\n31.1*\n\n \n\n[Certificate of the Chief Executive Officer of Aytu BioPharma, Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ex_918585.htm)\n\n31.2*\n\n \n\n[Certificate of the Chief Financial Officer of Aytu BioPharma, Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ex_918586.htm)\n\n32.1**\n\n \n\n[Certificate of the Chief Executive Officer and the Chief Financial Officer of Aytu BioPharma, Inc. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ex_918587.htm)\n\n101.INS*\n\n \nXBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n\n101.SCH*\n \nInline XBRL Taxonomy Schema Linkbase Document.\n\n101.CAL*\n \nInline XBRL Taxonomy Calculation Linkbase Document.\n\n101.DEF*\n \nInline XBRL Taxonomy Definition Linkbase Document.\n\n101.LAB*\n \nInline XBRL Taxonomy Labels Linkbase Document.\n\n101.PRE*\n \nInline XBRL Taxonomy Presentation Linkbase Document.\n\n104*\n\n \n\nCover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).\n\n \n\n*    Filed herewith.\n\n**  Furnished herewith.\n\n \n\n39\n\n[Table of Contents](#toc)\n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\nAYTU BIOPHARMA, INC.\n\n \n \n \n\nDate: May 13, 2026\n\nBy:\n\n/s/ Joshua R. Disbrow\n\n \n \n\nJoshua R. Disbrow\n\n \n \nChief Executive Officer\n\n \n \n*(Principal Executive Officer)*\n\n \n \n \n\nDate: May 13, 2026\nBy:\n/s/ Ryan J. Selhorn\n\n \n \nRyan J. Selhorn\n\n \n \nChief Financial Officer\n\n \n \n*(Principal Financial and Accounting Officer)*\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n40"}